IN.PACT AV access randomized trial: Japan cohort outcomes through 12 months.
Ther Apher Dial
; 27(4): 682-693, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-36606683
ABSTRACT
PURPOSE:
There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug-coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months. MATERIALS ANDMETHODS:
Participants were treated with DCB (n = 58) or standard non-coated percutaneous transluminal angioplasty (PTA) balloons (n = 54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety.RESULTS:
Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p = 0.013).CONCLUSION:
In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Cardiovasculares
/
Angioplastia com Balão
/
Doença Arterial Periférica
/
Dispositivos de Acesso Vascular
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Humans
País/Região como assunto:
Asia
Idioma:
En
Revista:
Ther Apher Dial
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão